Cumbo Alexander 4

What Happened

• Alexander Cumbo, President & CEO and a director of Solid Biosciences (SLDB), had 30,031 restricted stock units (RSUs) convert into common shares on Feb 13, 2026 (conversion recorded as a derivative exercise/convert). On Feb 18, 2026 he sold 16,644 of those shares in an open-market, sell-to-cover transaction for a weighted-average price of $5.82, generating approximately $96,923 in gross proceeds.
• The conversion/derivative entry shows no cash exercise price (recorded at $0.00), consistent with RSUs converting to shares rather than stock-option exercises requiring cash.

Key Details

• Transaction dates: RSU conversion/exercise on 2026-02-13; open-market sale on 2026-02-18.
• Sale: 16,644 shares at a weighted-average price of $5.82; total proceeds ≈ $96,923. Reported sale prices ranged from $5.23 to $6.14.
• Conversion: 30,031 RSUs converted into shares (no cash paid on conversion).
• Reason for sale: Sell-to-cover to satisfy withholding taxes after RSU vesting; executed under a durable automatic sales instruction (sell-to-cover) adopted Aug 18, 2024 — not a discretionary trade.
• RSU terms: RSUs were granted Feb 13, 2024 and vest 25% each year over four years (anniversary vesting).
• Shares owned after transaction: not specified in the provided filing.
• Filing timeliness: The report was filed Feb 18, 2026 while the primary conversion occurred Feb 13, 2026 — this appears to be later than the SEC’s standard two-business-day Form 4 filing window for that earlier transaction.

Context

• These were RSU conversions followed by a routine sell-to-cover sale to pay withholding taxes. That pattern (RSUs vest → automatic sell-to-cover) is common and does not necessarily signal voluntary insider selling for investment reasons.
• For retail investors, purchases are generally a stronger signal than routine sales tied to tax withholding; this filing documents standard compensation vesting mechanics rather than a discretionary divestiture.